Ontario was the first province in Canada to fund
gene expression profiling tests.
Gene expression profiling tests, such as Oncotype Dx, analyze the patterns of 21 different genes within cancer cells to help predict how likely it is that a women's cancer will recur within 10 years after initial treatment and how beneficial chemotherapy will be to her.
«Barriers to obtaining
gene expression profiling test heightened perceived value.»
Oncologists welcome
gene expression profiling tests as an added tool in deciding whether women with early - stage breast cancer should have chemotherapy, a new study has found.
Gene expression profiling tests such as Oncotype Dx can help differentiate women who might benefit from chemotherapy versus those that might not.
PHOTO: Harbour LaboratoryUsing very small amounts of tumor tissue collected by a needle biopsy, doctors can conduct
gene expression profile testing to determine the likelihood that an ocular melanoma tumor will spread beyond the eye.
Not exact matches
Using
gene expression profile (GEP)
tests like Oncotype DX to inform treatment decision - making for breast cancer is likely to be less cost - effective in community oncology practice than previous estimates had suggested, according to an economic simulation analysis published in the Journal of Clinical Oncology.
Then we
tested functionality of oocytes matured in vitro by assessing the ability to develop to the blastocyst stage, and by comparing the
gene expression profiles of parthenogenic embryos and those obtained from IVF / ICSI.